203 related articles for article (PubMed ID: 23703616)
21. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid).
Clement B; Mau S; Deters S; Havemeyer A
Drug Metab Dispos; 2005 Nov; 33(11):1740-7. PubMed ID: 16118330
[TBL] [Abstract][Full Text] [Related]
22. The molybdenum cofactor enzyme mARC: Moonlighting or promiscuous enzyme?
Llamas A; Chamizo-Ampudia A; Tejada-Jimenez M; Galvan A; Fernandez E
Biofactors; 2017 Jul; 43(4):486-494. PubMed ID: 28497908
[TBL] [Abstract][Full Text] [Related]
23. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans.
Kurian JR; Bajad SU; Miller JL; Chin NA; Trepanier LA
J Pharmacol Exp Ther; 2004 Dec; 311(3):1171-8. PubMed ID: 15302896
[TBL] [Abstract][Full Text] [Related]
24. Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Froriep D; Clement B; Bittner F; Mendel RR; Reichmann D; Schmalix W; Havemeyer A
Xenobiotica; 2013 Sep; 43(9):780-4. PubMed ID: 23379481
[TBL] [Abstract][Full Text] [Related]
25. Molybdenum.
Novotny JA; Peterson CA
Adv Nutr; 2018 May; 9(3):272-273. PubMed ID: 29767695
[TBL] [Abstract][Full Text] [Related]
26. The mitochondrial amidoxime reducing component-from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target.
Struwe MA; Scheidig AJ; Clement B
J Biol Chem; 2023 Nov; 299(11):105306. PubMed ID: 37778733
[TBL] [Abstract][Full Text] [Related]
27. Efficient Reduction of Vertebrate Cytoglobins by the Cytochrome b
Amdahl MB; Sparacino-Watkins CE; Corti P; Gladwin MT; Tejero J
Biochemistry; 2017 Aug; 56(30):3993-4004. PubMed ID: 28671819
[TBL] [Abstract][Full Text] [Related]
28. The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
Gruenewald S; Wahl B; Bittner F; Hungeling H; Kanzow S; Kotthaus J; Schwering U; Mendel RR; Clement B
J Med Chem; 2008 Dec; 51(24):8173-7. PubMed ID: 19053771
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes.
Kubitza C; Bittner F; Ginsel C; Havemeyer A; Clement B; Scheidig AJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):11958-11963. PubMed ID: 30397129
[TBL] [Abstract][Full Text] [Related]
30. The History of mARC.
Clement B; Struwe MA
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375270
[TBL] [Abstract][Full Text] [Related]
31. The role of porcine cytochrome b5A and cytochrome b5B in the regulation of cytochrome P45017A1 activities.
Billen MJ; Squires EJ
J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):98-104. PubMed ID: 19101629
[TBL] [Abstract][Full Text] [Related]
32. Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
Heintze T; Klein K; Hofmann U; Zanger UM
Sci Rep; 2021 Jan; 11(1):1000. PubMed ID: 33441761
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC; Trepanier LA
Pharmacogenet Genomics; 2010 Jan; 20(1):26-37. PubMed ID: 19997042
[TBL] [Abstract][Full Text] [Related]
34. Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: consequences for the prodrug concept "amidoximes instead of amidines".
Bauch E; Reichmann D; Mendel RR; Bittner F; Manke AM; Kurz P; Girreser U; Havemeyer A; Clement B
ChemMedChem; 2015 Feb; 10(2):360-7. PubMed ID: 25512261
[TBL] [Abstract][Full Text] [Related]
35. The Zebrafish Cytochrome
Amdahl MB; Petersen EE; Bocian K; Kaliszuk SJ; DeMartino AW; Tiwari S; Sparacino-Watkins CE; Corti P; Rose JJ; Gladwin MT; Fago A; Tejero J
Biochemistry; 2019 Jul; 58(29):3212-3223. PubMed ID: 31257865
[TBL] [Abstract][Full Text] [Related]
36. Study of Different Variants of Mo Enzyme crARC and the Interaction with Its Partners crCytb5-R and crCytb5-1.
Chamizo-Ampudia A; Galvan A; Fernandez E; Llamas A
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335548
[TBL] [Abstract][Full Text] [Related]
37. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
[TBL] [Abstract][Full Text] [Related]
38. Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme.
Havemeyer A; Bittner F; Wollers S; Mendel R; Kunze T; Clement B
J Biol Chem; 2006 Nov; 281(46):34796-802. PubMed ID: 16973608
[TBL] [Abstract][Full Text] [Related]
39. Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
Kotthaus J; Wahl B; Havemeyer A; Kotthaus J; Schade D; Garbe-Schönberg D; Mendel R; Bittner F; Clement B
Biochem J; 2011 Jan; 433(2):383-91. PubMed ID: 21029045
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the amidoxime reducing components ARC1 and ARC2 from Arabidopsis thaliana.
Maiber L; Koprivova A; Bender D; Kopriva S; Fischer-Schrader K
FEBS J; 2022 Sep; 289(18):5656-5669. PubMed ID: 35366369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
